T he prognosis of patients who develop peritoneal carcinomatosis (PC) from colorectal cancer has recently been improved with complete cytoreductive surgery (CCRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The 5-year overall survival rate is now between 40% and 48%. 1, 2 If this new therapeutic approach is performed earlier when the extent of peritoneal seeding is limited, it is far more efficient and causes less morbidity. [1] [2] [3] [4] [5] Even better results could therefore be achieved if PC were treated at an early stage.
Unfortunately, PC is usually diagnosed late in the disease progression because symptoms occur at an advanced stage. Also, current imaging techniques are unable to detect PC at an early stage and it can only be diagnosed by exploring the peritoneal cavity during laparotomy or laparoscopy. Such surgical exploration cannot be proposed to all the patients systematically and periodically but possibly to subgroups of patients at high risk of developing PC rapidly. Some subgroups of high-risk patients have been defined in the literature: those with synchronous limited PC with the primary tumor, with synchronous ovarian metastases, and with a perforated primary tumor. 6 -10 For these high-risk patients, it has become logical to us to test second-look surgery in an attempt to detect PC at an early stage, and to treat it at a low risk with CCRS combined with HIPEC.
The aim of this prospective study was to analyze the impact of second-look surgery in an attempt to treat earlystage PC in a series of patients at high risk of developing the disease after resection of a primary colorectal cancer.
PATIENTS AND METHODS
This was a prospective study, and all the patients were systematically informed of the aim of the study before the second-look procedure and gave their consent.
Inclusion Criteria
We included patients who underwent curative resection of their primary colorectal tumor, which was (i) associated to minimal PC, which was macroscopically evident, completely resected at the same time as the primary and histologically examined or (ii) associated to ovarian metastasis (also resected), synchronous with the primary or (iii) perforated inside the peritoneal cavity. In this group of patients, those who did not present with any sign of recurrence before the second-look procedure at tumor marker determination on imaging studies performed during the month preceding the second-look surgery and analyzed by 2 experienced radiologists were selected for the study. Imaging studies included a computed tomography (CT) scan of the abdomen and the pelvis with oral and intravenous contrast agent, and a thoracic CT scan. The positron emission tomography (PET) scanner was not required in these asymptomatic patients. Only patients with a good general status (World Health Organization ͓WHO͔ Performance Status Ͻ2) able to undergo CCRS combined with HIPEC were included.
Design of the Trial
After the surgical resection of the primary tumor, these "high-risk PC" patients commonly received adjuvant oxaliplatin-or irinotecan-based chemotherapy regimens for 6 months. Six months later, if the complete work-up was negative (no clinical symptoms or any CT scan abnormality or increasing blood tumor markers), second-look surgery was proposed to the patients and was performed during the following month. Laparotomy was performed to reopen the dissection planes of the first operation and to palpate the tissues. A median xyphopubic incision was systematically used, and the abdominal cavity was completely explored. The patients who had macroscopic PC, confirmed by a frozen section analysis, underwent CCRS combined with HIPEC. If there was no macroscopic PC, HIPEC was only performed in patients whose synchronous PC was resected with the primary tumor. HIPEC was not performed in the other cases.
At laparotomy, the mean number of involved peritoneal areas and the mean peritoneal score for the extent of the peritoneal seeding (Sugarbaker's score which can range from 1 to 39) 3 were calculated for each patient. The macroscopically detectable peritoneal disease had to be completely resected before administering HIPEC. Oxaliplatin was administered alone intraperitoneally in an open abdominal cavity (Coliseum technique) at a dose of 460 mg/m 2 in 2 L/m 2 of iso-osmotic 5% dextrose, 11 or at a dose of 360 mg/m 2 when associated with irinotecan at a dose of 360 mg/m 2 . 12, 13 The intraperitoneal temperature was homogeneous at 43°C (range, 42-44°C) for 30 minutes. Patients received an intravenous perfusion of 5-fluorouracil (400 mg/m 2 ) with leucovorin (20 mg/m 2 ) just before starting HIPEC. 12, 13 
Follow-up of Patients After Second-look Surgery and Long-term Results
Patients were followed after the second-look procedure in the classic fashion every 3 months with a clinical examination, imaging studies, and blood tumor marker determination.
The statistical analysis was performed using the 2 test for quantitative values. Statistical significance was set at a P value less than 0.05.
RESULTS
Between April 1999 and April 2006, 29 patients underwent second-look surgery in our institute approximately 1 year after the first surgical procedure for curative treatment of a primary tumor presenting a "high-risk of giving rise to PC."
The mean interval between resection of the primary and second-look surgery was 13 months (range, [12] [13] [14] . It was 12 months in 7 patients, 13 months in 16 patients, and 14 months in 6 patients.
Three Subgroups of Patients According to Their High-risk Factor for PC
The first subgroup (PC group) of 16 patients had macroscopic PC synchronous with the primary, which were completely resected. The second subgroup (ovarian group) of 4 patients only had ovarian metastases from the primary without PC. In the third subgroup (perforated group) of 9 patients, the primary tumor was perforated in the peritoneal cavity.
All patients received adjuvant systemic chemotherapy over 6 months. The characteristics of the primary tumors, their main risk factor for PC, adjuvant chemotherapy, the interval between the first and second surgical procedures, and second-look surgery are reported in Table 1 .
Peritoneal Carcinomatosis at Second-look Surgery
Macroscopic PC was discovered in 16 (55%) of these asymptomatic patients during the second-look procedure. Of these 16 patients, 10 were from the PC group, 3 were from the ovarian group, and 3 from the perforated group. All these 16 patients underwent CCRS plus HIPEC (Fig. 1 ). The mean number of involved peritoneal areas was 5.6 (range,1-9 among the 13) and the mean peritoneal score for the extent of the peritoneal seeding was 10.2 (range, 2-24). The details concerning CCRS are reported in Table 2 . For the 13 remaining patients with no detectable macroscopic PC, HIPEC was performed in 6 because they were in the PC group. Thus, HIPEC was performed in 22 of 29 patients, and complete exploration of the peritoneal cavity without HIPEC in 7. The mean duration of surgery was longer in the CCRS plus HIPEC group (385 minutes ͓range, 240 -519͔) than in the HIPEC group (328 minutes ͓range, 280 -420͔) or the laparotomy group (295 minutes ͓range, 188 -360͔) (P Ͻ 0.01). The mean blood loss was higher in the CCRS plus HIPEC group (558 mL, ͓range, 100 -1100͔) than in the HIPEC group (305 mL ͓range, 100 -650͔) or in the laparotomy group (258 mL ͓range, 100 -455͔) (P Ͻ 0.01).
Mortality and Morbidity
No postoperative mortality was observed. Postoperative complications (grade II to IV) 14 occurred in 38% of the patients. Extra-abdominal complications (all grade II) occurred in 9 patients (31%) and included transient grade 3 hematological toxicity (n ϭ 2) in the CCRS plus HIPEC group, lung infections (n ϭ 2), infection of the central catheter (n ϭ 1), and urinary infections (n ϭ 4). Two patients (14%) in the CCRS plus HIPEC group developed abdominal abscesses requiring percutaneous drainage. No intra-abdominal complication occurred after systematic prophylactic HIPEC or after explorative laparotomy. The mean hospital stay was 16.4 days for the entire group (range, 7-24). It was 18.3 days (range, 14 -24) 17.5 days (range, 14 -23) and 11.2 days (range, 7-17), respectively, for the CCRS plus HIPEC group, for the HIPEC group, and for the explorative laparotomy group.
Follow-Up
Median follow-up after second-look surgery was 27 months (mean, 35 Ϯ 9.5 months; range, 6 -96). No patient was lost to follow-up. Overall results are reported in Figure 1 . Among the 16 patients with PC at second-look surgery, treated with CCRS plus HIPEC, 8 are free of disease, 4 relapsed with PC, associated with distant metastases in 2 cases, and 4 developed visceral metastases. Among the 13 patients without PC at second-look surgery, none of the 6 treated with systematic prophylactic HIPEC developed PC and 5 of these 6 patients are free of disease. In the remaining 7 patients who did not receive HIPEC, 3 developed PC and 4 are free of disease.
The disease status of the 16 patients in the PC group, the 4 patients in the ovarian group, and the 9 patients in the perforated group is reported in Figures 2, 3 , and 4, respectively.
DISCUSSION
This second-look policy in colorectal patients at high risk of developing PC, without any apparent clinical or imaging abnormality, effectively led to the discovery of macroscopic PC in 55% of the patients and allowed early treatment with curative attempt with CCRS plus HIPEC.
Between 1948 to 1961, the team at the University of Minnesota systematically proposed a second-look procedure to colorectal patients with a pT4 tumor or with positive lymph nodes, 6 to 12 months after curative resection of the primary tumor. 15, 16 Among the 60 patients with colon cancer, disease was found in 42% after second-look surgery, with PC in less than half of them, and finally, only 2 patients remained free of disease. 15 The major problem with this second-look approach, originally described by Wangensteen, was operative mortality (7%) and rather high morbidity. 17 Nonetheless, those studies provided interesting information on the history of this disease but it failed to target efficaciously patients at On the contrary, in our study early PC was discovered at an early treatable stage in 55% of the second-look procedures performed 1 year after resection of the primary. The second-look strategy should therefore be reconsidered, particularly after proof that CCRS plus HIPEC are able to cure colorectal patients with PC 1-5 with better targeting of highrisk patients. We obtained a 5-year survival rate of 48% with CCRS plus HIPEC in 30 patients with macroscopic PC 1 and Verwaal et al obtained a survival rate of 43% in 59 patients with completely cytoreduced disease. 2 Moreover, it has largely been demonstrated that the survival results with CCRS plus HIPEC are far better when PC is limited in extent. [1] [2] [3] [4] [5] This is a strong argument in favor of attempting to detect and treat PC at an early stage.
Detecting PC at an early stage is not currently possible in most cases because of the absence of symptoms and suboptimal imaging studies. CT examination of the abdomen and the pelvis with oral and intravenous contrast agent remains the state-of-art imaging modality for the detection of peritoneal tumors. Its accuracy is comparable to that of magnetic resonance imaging and PET. However, its sensitivity is considerably lower when tumor deposits are smaller than 1 cm (9%-24%). 18, 19 In this study, although imaging studies were analyzed twice by trained radiologists, PC was not diagnosed preoperatively in 55% of cases.
Only a laparotomy with a complete and systematic exploration of the abdominal cavity is able to detect early-stage PC. The entire abdominal cavity cannot be explored and palpated extensively during laparoscopy, which does not allow one to reopen all previous dissection planes, and is therefore not indicated. This systematic and very meticulous exploration is long, as shown by the mean duration of surgery (295 minutes) in our group who only underwent a laparotomy.
As this second-look strategy is not bereft of drawbacks for the patients and is also costly to society, it is essential that it be proposed exclusively to selected patients at high-risk of developing PC. After studying the extensive data reported in literature about the risk of developing metachronous PC, we selected 3 subgroups of high-risk patients in whom the risk of relapse with PC is far greater than that of relapsing in the liver or lungs. The first subgroup comprised patients who already presented with macroscopically proven PC at initial surgery. Despite complete resection during initial surgery, their risk of developing a relapse with PC is close to 90%. 6 -8 With 63% of patients presenting with PC at 13 months, our results confirm these data. The second subgroup comprised patients with ovarian metastasis at first-look surgery; as in the case of stage 3 ovarian cancers, the theoretical risk of presenting with already established microscopic PC is high. Our results also confirm this point, because, ultimately, all patients with synchronous ovarian metastases developed PC. The third subgroup comprised patients with a perforated primary tumor (spontaneous or inadvertent intraoperative perforation) at first-look surgery. A local recurrence occurred in 62% to 87% of these patients, with a peritoneal component in 29% to 75% of the cases. 9 -11 Once again, our results corroborate these 
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Annals of Surgery • Volume 247, Number 3, March 2008 data, because, ultimately, 5 of the 9 patients with a perforated primary developed PC, which was isolated in 3 cases. Obstructive tumors at first-look surgery were not considered eligible for our trial because we thought those data were not sufficiently conclusive regarding the risk of developing PC. They could eventually be considered for such a strategy in the future if we consider the series by Willet et al, 9 in which 17 of 77 patients (22%) with obstructive colonic tumors later developed PC. Finally, with hindsight we can safely conclude that our 3 selection criteria for patients at high risk of developing PC were judicious. We adopted an interval of 1 year between first-look and second-look surgery for the following reasons: most importantly, all except 1 patient had a stage III or IV (UICC) primary tumor requiring standard systemic adjuvant chemotherapy over 6 months. 20, 21 Adjuvant chemotherapy is efficient and arrests the growth of microscopic residual disease. However, we consider that 6 further months are necessary to allow peritoneal seeding to become macroscopically detectable. However, a 6-month period corresponds to approximately 2 doubling-time periods, 22, 23 which means that the size of residual tumor seeding would be multiplied by 4. One could consider performing second-look surgery at 18 months instead of 12 months with the hope of detecting PC more easily. However, although the likelihood of not detecting PC would be reduced with a longer interval, the risk of allowing early PC to progress would increase, making it more difficult to treat and cure the disease.
The benefit and efficacy of this new approach seems to be good considering that we detected and treated asymptomatic PC in 55% of selected patients. Furthermore, this approach allowed us to detect PC at an early stage, which was confirmed by the low peritoneal index in this series (mean, 10.2) compared with a mean peritoneal index of 14 to 24 in series treating symptomatic colorectal PC. [1] [2] [3] [4] [5] In this study, treatment of PC at an early stage resulted in no postoperative mortality, a low rate of grade III-IV morbidity (14%), and a short hospital stay. This is in contrast with the usual higher complication rates reported in the literature after CCRS plus HIPEC for more advanced PC: postoperative grade III-IV toxicity and complications ranged from 23% to 40%, whereas treatment-related mortality ranged from 4% to 8%. 1, 24, 25 Thus, the classic high morbidity rates observed after CCRS plus HIPEC appear to be mainly correlated with the extent of the peritoneal disease and the extent of surgery, and therefore could be decreased if patients with PC were treated at an early stage.
In the present series, follow-up is currently too limited to definitely conclude that a curative benefit can be derived from this new strategy. In fact, initially, our aim at the outset was to obtain preliminary results concerning the following 3 points: (i) to determine the frequency of PC at second-look surgery performed at 1-year, (ii) to evaluate our selection criteria for patients at high risk of developing PC, and (iii) to study the mortality and morbidity caused by this approach. We obtained clear and encouraging results regarding these 3 points, which have prompted us to pursue our investigation of this new strategy.
Finally, it already seems justified to propose such a second-look procedure to patients who present with minimal PC or an ovarian metastasis at first-look surgery. The question of whether to propose second-look surgery earlier and/or to perform HIPEC even when there is no detectable PC for these patients can be debated. We performed systematic prophylactic HIPEC in 6 patients, and none of them developed PC. In contrast, the patient who presented an ovarian metastasis at first-look surgery, but who did not receive HIPEC during the second-look (no detectable disease), subsequently developed isolated PC. The question of early and systematic second-look surgery with prophylactic HIPEC should be discussed for these 2 subgroups of patients, but also prophylactic HIPEC during surgery resecting the high-risk primary tumor. For the patients who had a perforated primary tumor during initial surgery, 5 had developed PC by the time the second-look procedure was performed or later. However, PC was isolated and accessible to CCRS plus HIPEC in only 3 patients. This subgroup seems to exhibit a different "natural history" than the other 2, with a higher risk of developing distant metastases associated with PC. Thus, the second-look strategy may not be indicated for these patients, and further data are warranted.
In conclusion, we showed that second-look surgery, performed 1 year after the first-look procedure in selected patients at high risk of developing PC, allows early detection of PC in 55% of asymptomatic patients and curatively intended treatment can then be easily performed. In our opinion, more extensive data and follow-up are clearly required before this second-look approach can be established as a standard in high-risk PC patients. However, our preliminary results encourage us to pursue this strategy and to evaluate it in a prospective multicenter trial.
